Furthermore, studies have illustrated that anti-angiogenic drugs can upregulate PD-L1 expression on tumor cells, remodel the immune microenvironment, and enhance the clinical effectiveness of ICIs (22, 23). This evidence concerns the gene CD274 and neoplasm.